Sign in
SCYX Stock Price, Chart, Stats & News
SCYNEXIS, Inc.
Save
SCYNEXIS, Inc. (SCYX) does not currently pay a dividend.
28.17M
Market cap
–
Current P/E
3.72x
Forward P/E
SCYX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -77.93% |
Pretax margin | -41.79% |
Net margin | -41.79% |
Effective tax rate | – |
ROA | -14.58% |
ROE | -19.05% |
D/E | 0.04x |
Interest coverage ratio | -33.10x |
SCYX valuation
P/E | – |
P/S | 1.76x |
P/B | 0.72x |
P/CF | -6.70x |
P/FCF | -6.87x |
P/OCF | -6.70x |
PEG | -0.06x |
EV multiple | 3.38x |
About
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Similar securities
Based on sector and market capitalization
Report issue